Abbott sees new a physician-patient dynamic ushered in by the “convergence of health and technology to empower human lives. Healthtech is at an inflection point. We’re creating a future that will bring care that is more personal and precise, and will take human capabilities to entirely new levels. A future where people can manage their own health—decentralize and democratize healthcare. With the right tools we can give everyone the best chance to live their best lives.”
Here are three examples:
Sherri Shepherd, (no relation to my family, too bad) co-host of The View whose family’s narrative of diabetes persists into her generation, offered a moving story of how Abbott’s FreeStyle Libre “changed my life—it didn’t hurt, I didn’t need the fingerpricks anymore, it gives me my readings right on my phone, it’s accurate and it holds me accountable. I’m breaking the multigenerational diabetes history in my family.”
Tyrone Morris, diagnosed with CHF in 2016 congestive heart failure, spoke of how Abbott’s CardioMEMS system helped monitor his care until he could get a life-changing heart transplant.
My favorite is the video of Kenya’s Eliud Kipchoge, an Olympic marathoner, the first ever to run a sub-two-hour marathon. He trained with Abbott’s Libre Sense glucose sport biosensor. I love his quotes! “Make discipline your lifestyle. Discipline is not a one-time event. Self-discipline is like building your muscle. Only the disciplined ones are free in life. If you aren’t disciplined, you are a slave to your moods. You are a slave to your passions. That’s a fact.”
The Medi-Vantage team can help you and your product development team uncover digital health unmet needs so that engineers can focus on engineering the device possible.
You can see the full articles at:
https://www.twice.com/industry/ces/abbotts-ford-speaks-about-the-lingo-of-human-powered-health
CONTACT US
LOOKING FOR A PARTNER WITH KEY INSIGHTS FROM CLINICIANS & HOSPITAL ADMINISTRATORS AND HOSPITAL CFOS?
OUR LAST THREE PROJECTS WERE:
What price premium can be charged for an upgraded legacy product in a commodity space?
Medtech price sensitivity analysis - hospital administrators and CFOs
M&A due diligence analysis: pricing for a new disruptive product